Mesoblast Limited (MESO) Q4 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Mesoblast Limited.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.990 -- 00:00:03.671 Good morning, good afternoon to Nisa 00:00:03.671 -- 00:00:08.334 Blast Financial Results and Operational Update for the half year ended December 31, 2023. 00:00:08.334 -- 00:00:10.015 With 00:00:10.015 -- 00:00:12.577 me on this call, 00:00:12.577 -- 00:00:17.640 Chief Medical Officer, Dr. Eric Rose, Interim Chief Financial Officer, 00:00:17.640 -- 00:00:22.663 Andrew Chapanel, and one of our Nisa Blast 00:00:22.663 -- 00:00:26.745 board members, Dr. Philip Krause. 00:00:29.215 -- 00:00:32.396 If we could go to slide four, please. 00:00:32.396 -- 00:00:36.917 A snapshot of the investment highlights of mesoblaster are on this slide. 00:00:36.917 -- 00:00:42.439 We're developing a novel allogeneic cell therapy technology platform to enable treatment 00:00:42.439 -- 00:00:45.420 without the need for donor matching or immunosuppression. 00:00:45.420 -- 00:00:47.460 The lead indications 00:00:47.460 -- 00:00:51.641 of our two platforms, Remy Stem Cell and Rex Linguistro Cell. 00:00:51.641 -- 00:00:56.783 Remy Stem Cell is being developed for both pediatric and adult steroid refractory acute 00:00:56.783 -- 00:01:02.068 graft-versus-host disease. For the pediatric indication, we've completed a single-arm 00:01:02.068 -- 00:01:07.712 pivotal phase three trial, which successfully met its primary endpoint. 00:01:07.712 -- 00:01:12.835 Long-term survival data shows durability of survival benefit for more than 00:01:12.835 -- 00:01:17.858 four years. New data from a second potency assay has been provided to the 00:01:17.858 -- 00:01:22.000 FDA, and we have an upcoming meeting scheduled 00:01:22.141 -- 00:01:23.962 during March. 00:01:23.962 -- 00:01:27.839 For adult steroid refractory acute GVHD, 00:01:27.839 -- 00:01:30.780 We are collabora...